Article

Protective Immunity Elicited by VP1 Chimeric Antigens of Bacterial Ghosts against Hand-Foot-and-Mouth Disease Virus

Saisai Gong 1,†, Nan Nan 1,†, Yakun Sun 1,2,†, Zhili He 1, Jiajia Li 1, Fanghong Chen 1, Tao Li 1, Nianzhi Ning 1, Jianxin Wang 1, Zhan Li 1, Deyan Luo 1,2,* and Hui Wang 1,2,*

1 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China; gby1738131995@163.com (S.G.); nannan163n@163.com (N.N.); syk_dyx@hotmail.com (Y.S.); lili892017173@163.com (Z.H.); 13024096923@163.com (J.L.); cfh880314@163.com (F.C.); litaobmi@126.com (T.L.); ningnianzhi@163.com (N.N.); jianxinwang1994@163.com (J.W.); yexi19881214@126.com (Z.L.)
2 Department of Microbiology, Anhui Medical University, Hefei 230000, China

* Correspondence: ldy612@126.com (D.L.); wanghui_dyx@hotmail.com (H.W.); Tel.: +86 10 66948532 (H.W.); Fax: +86 10 66948532 (H.W.)
† These authors contributed equally to this article.

Received: 18 December 2019; Accepted: 28 January 2020; Published: 1 February 2020

Abstract: This study was designed to evaluate the immunogenicity and protective efficacy of two VP1 chimeric antigens of bacterial ghosts. Inoculation of the two VP1 chimeric antigens of bacterial ghosts into BALB/c mice markedly elicited humoral and mucosal immune responses. The specific antibodies induced by the chimeric ghosts protected mice not only against the virus that causes hand-foot-and-mouth disease but also against \textit{E. coli} O157:H7 bacterial infection. In comparison with the negative control, immunization with the chimeric ghosts protected mice against two LD₅₀ hand-foot-and-mouth disease viral infection. In addition, this specific immunity also protected the pups of pregnant mice immunized with the VP1 chimeric antigens of bacterial ghosts against 20 MLD \textit{E. coli} O157:H7 infection. Taken together, the results of this study verify for the first time that the VP1 chimeric antigens of bacterial ghosts are target candidates for a new type of vaccine against hand-foot-and-mouth disease. Additionally, this vaccine strategy also elicited a stronger immune response against \textit{E. coli} O157:H7.

Keywords: bacterial ghost; hand, foot, and mouth disease; enterovirus 71; Coxsackie virus

1. Introduction

Hand-foot-and-mouth disease (HFMD), a global infectious disease caused by intestinal viruses, has differing outbreak intensities all over the world [1]. Similar to other intestinal pathogens, host resistance to the HFMD virus relies mainly on innate and mucosal immunity [2,3]. The mature B lymphocytes that secrete serum-neutralization antibodies is the most important protective response in infected hosts [4]. A vaccine that is nonpathogenic to humans, but effective in stimulating a broad protective immune response, is needed to control HFMD. To develop this type of HFMD vaccine, several research groups are pursuing different strategies, including the development of subunit vaccines and overexpression of protective homologous antigens [5–8]. Another new strategy for developing safe and efficacious vaccines is immunization with bacterial ghosts (BGs) carrying a protective antigen. BGs are produced by the expression of PhiX174 lysis gene \textit{E} and result in cytoplasmic loss and cellular lysis [9]. BGs maintain the cellular morphology and native antigenic surface structure [10] and possess the adjuvant property of bacteria [11,12]. The effects of BG vaccines
have been described in various pathogens, such as *Vibrio cholera* [13], *Helicobacter pylori* [14], and *Escherichia coli* O157:H7 [15].

HFMD is primarily caused by enterovirus 71 and the Coxsackie virus, both of which are in the *Enterovirus* genus. Studies have shown that using the VP1 capsid protein of the two viruses as an antigen provides protective immunity against viral infections in a murine model [6,16]. In this study, linear VP1 of the enterovirus 71 (EVP1) and the Coxsackie virus (CVP1) were displayed on the surface of *E. coli* O157:H7 BGs based on the sandwich vector pSompA [17]. The outer membrane protein A (OmpA) of *E. coli* was used in order to construct a novel candidate vaccine named EVP1 bacterial ghosts (EGBs) and CVP1 bacterial ghosts (CBGs). The immunogenicity, protective ability, and immunologic mechanism of these vaccines in the challenge of the HFMD virus and enterohemorrhagic *E. coli* O157:H788321 (EHEC) were analyzed in this study.

2. Materials and Methods

2.1. Bacterial Strains, Cells, Plasmids and Virus

Two *E. coli* strains were grown in Luria–Bertani (LB) broth or agar (Oxoid LTD, Basingstok, Hampshire, England) supplemented with 100 μg/mL of ampicillin for selection of recombinant plasmid at 37 °C. The bacterial strain *E. coli* O157: EDL 933 for bacterial ghosts preparation was kept in our lab. The bacterial strain *E. coli* O157: H788321 for challenge was also kept in our lab. Two wild-type strains ATCC O157: H788321 were purchased from the ATCC center (American Type Culture Collection). A Vero E6 cell line and a HEp-2 cell line were kept in our lab. The expression vector pGEX was purchased from Transgen Inc. (Beijing, China), and display vector pSOMPA and lysis plasmid pLysisE were constructed by our lab [15]. Enterovirus 71 (EV71; GenBank: JQ514785.1) and coxsackievirus B3 (CB3; GenBank: M88483.1), on the basis of which vaccines have been developed, were kept in our lab.

2.2. Mice

All animal studies were conducted in accordance with the Beijing Institute of Microbiology and Epidemiology Animal Care and Use Committee guidelines (IACUC 2012). BALB/c wild type mice (5-week-old, weighing 14–16 g) were obtained from our institute’s Laboratory Animal Center, Beijing, China. All experimental mice were bred in a specific pathogen-free facility at our institute. Experimental mice were matched for age and sex and cared for according to the guidelines of our institute. Mice were monitored and weighed at least once daily after initiating infection. Recumbent mice, and mice that lost more than 30% weight, were considered moribund and euthanized.

2.3. Construction and Preparation of pOEVP1 and pOCVP1.

Full-length open reading frames of the VP1 genes from enterovirus 71 (EVP1) and coxsackievirus B3 (CVP1) were amplified with PCR. The 234–325 amino acids of OmpA amplified from *E. coli* O157:H7 933 strain. The PCR primers were designed as follows: EVP1, Forward, 5’- GAATTCGGAGATAGGGTGGC-3’, Reverse, 5’- GAGCTCAAGAGTGGTGATCG-3’. CVP1 Forward, 5’- GAATTCGGCCCAGTGGAAGAC-3’, Reverse, 5’- GAGCTCAAATGCGCCCGTAT-3’. The two fragments EVP1 and OmpA were digested by EcoRI/SacI (New England Biolabs, Ipswich, MA, USA) and then ligated into the expression vector pGEX between XmaI and NcoI restriction sites to generate the expression plasmid pOEVP1. The two fragments CVP1 and OmpA were digested by EcoRI/SacI and then ligated into the expression vector pGEX between XmaI and NcoI restriction sites to generate the expression plasmid pOCVP1. The resulting constructs were transformed into *E. coli* O157:H7 EDL 933 for bacterial ghosts preparation.

2.4. Preparation of Bacterial Ghosts and Whole Cells [18]

The pOEVP1 and pOCVP1 plasmids were transformed into *E. coli* O157:H7EDL 933 as novel competent cells. LB-medium containing ampicillin was inoculated with *E. coli* O157:H7 EDL 933
overnight culture, transformed with the kanamycin resistance and thermolysis plasmid pLysisE to generate BGs (named EBGs and CBGs). *E. coli* O157:H7 EDL933 strain without pOEVP1 or pOCVP1 plasmid were prepared to BGs as control (named OBGs). In detail, 200 ml of LB-medium containing 100 μg/mL ampicillin and 100 μg/mL kanamycin was inoculated with 5 mL of each *E. coli* strain containing plasmids. Grown up to OD<sub>600</sub> 0.3, the cultures of EBGs and CBGs were induced by isopropyl β-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM at 28 °C. The induction of lysis was achieved by shifting the temperature from 28 to 42 °C when the OD<sub>600</sub> reached 0.6, and the procedure was monitored by the optical densities. The lysis rate based on colony-forming units (CFU) and the morphous of EBGs and CBGs were detected as described previously [19]. Subsequently, BGs vaccine candidates were prepared by the repeated freezing and thawing method to get rid of the surviving bacteria, and then centrifuged 10 min and washed twice in ice-cold buffer (25 mM TBS, Tris-Buffered Saline). These steps may need to be repeated one more time. For long term storage, bacterial ghosts should be lyophilized. The absence of viable cells in the lyophilized samples was determined using colony-forming units.

2.5. Analysis of Antigens by Fluorescence Activating Cell Sorter (FACS)

Phosphate buffered solution (PBS) containing mouse anti-EVP1/CVP1 immunoglobin G was incubated with EBGs and CBGs for 1 h, respectively. Then, the FITC-labeled goat anti-mouse IgG was added and incubated for another 1 h as a second antibody, according to the first antibody, respectively. After processing, the labeled EBGs and CBGs were incubated with 10<sup>6</sup> HEP-2 cells for 4 h. Finally, these cells were harvested and re-suspended with FACS buffer, and 1 × 10<sup>5</sup> HEP-2 cells were detected by flow cytometry. The OBGs cells were used as control.

2.6. Analysis of Cytotoxicity by MTT

Cytotoxicity assays of lyophilized EBGs and CBGs were performed by MTT assay on Vero E6 cells. Serial diluted (1:10) EBGs and CBGs were applied on a Vero E6 cell monolayer and incubated at 37 °C (CO2) for 36 h. Then, 100 μL/well 0.5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide were added and incubated for another 4 h to produced formazan crystals. The produced formazan crystals were re-suspended by dimethyl sulphoxide (DMSO, 150 μL/well), and the absorbance at 570 nm was detected. The OBGs and *E. coli* O157:H7EDL 933 were used as controls.

2.7. Mice Immunization and Challenge

All animal studies were conducted in accordance with the Beijing Institute of Microbiology and Epidemiology Animal Care and Use Committee guidelines. Three-week-old male and female BALB/c mice were obtained from our institute’s Laboratory Animal Center and divided into groups randomly (20 mice/group). All experimental mice were bred in a specific pathogen-free facility at our institute. Experimental mice were matched for age and sex and cared for according to the guidelines of the institute. The mice were intragastrically administrated with 0.1 mg (corresponding to 10<sup>6</sup> CFU) of EBGs and CBGs, which were resuspended in 100 μl of PBS on day 0 for the primary injection and day 14 for boost vaccinations. PBS alone was administrated to the vehicle control group. Twelve mice from each group were then challenged intragastrically 14 days after booster with 20 LD<sub>50</sub> (2 × 10<sup>9</sup> CFU) or 50 LD<sub>50</sub> (5 × 10<sup>9</sup> CFU) of viable *E. coli* O157:H788321 strain. Adult mice were resistant to EV71 (or CB3) administrations.

Eight mice from each group were separated and bred for the subsequent study. The pups were used for a virus challenge study. The experimental endpoint was determined, as previously described [20]. One-day-old mice were used to examine the role of maternal antibodies in challenge studies. For maternal immunization, the BALB/c suckling mice possessing passively-transferred maternal EV71 or CB3 antibodies were challenged 1 day after birth with the virus of EV71 and CB3. The mice were observed daily for the occurrence of mortality as the experimental endpoint.

2.8. Detection of Specific Antibodies
The IgA/IgG of serum and irrigating solution specific to OBGs and proteins (intimin, EVP1, and protein CVP1) were measured by enzyme-linked immunosorbent assay. The presence of serum IgG and of the subtypes IgG1, IgG2a, IgG2b, and IgG3 specific to vaccine candidates was determined by indirect ELISA. The BGs (EBGs and CBGs, 0.1 mg/mL) and purified proteins (intimin, EVP1, and CVP1, 0.1 mg/mL) were coated in 96-well plates overnight at 4 °C, respectively. Serum samples were serially diluted in 2-fold dilutions from 1:10 to 1:20480. The endpoint dilution titer was calculated as the serum dilution resulting in an absorbance reading of 0.2 units above background. Goat anti-mouse IgA-HRP (Sigma, 1:5000) or goat anti-mouse IgG-HRP (Sigma, 1:5000) were used as the detection antibodies. The reactions were developed with TMB (3,3',5,5'-Tetramethylbenzidine) and stopped with 2 M H2SO4. The absorbance at 450 nm was detected.

2.9. Statistical Analysis.

Statistical analyses were performed using the program Prism 5.0 (GraphPad Software, Inc., LaJolla, California, CA, USA). Values are expressed as mean ± SD. Data were analyzed by unpaired Student’s t-test (normal distribution) or one-way ANOVA followed by Dunnett’s multiple comparison test. Survival data were analyzed by log-rank tests. Values of \( p < 0.05 \) are considered to be statistically significant.

3. Results

3.1. Preparation and Evaluation of the Chimeric BG Vaccine Candidates

We constructed specific BG vaccine candidates, EBG and CBG, in order to compare the relative roles of these BGs vaccine candidates in inducing an immune response and protective immunity against HFMD virus infection. The expression plasmid pOEVP1 containing 1990 bp of the OEVP1 gene was constructed, and the co-transformation of plasmids pOEVP1 and pLysE successfully generated the vaccine strain of EBGs. The expression plasmid pOCVP1 containing 1950 bp of the OCVP1 gene was constructed, and the co-transformation of plasmids pOCVP1 and pLysE successfully generated the vaccine strain of CBGs. The OD 600 of both EBGs and CBGs was reduced constantly after a shift in temperature. The precipitate 1 h after induction was harvested in order to evaluate the lysis rate, which was counted as 99.99% ± 0.01% (Figure 1A,B). The morphology of EBGs and CBGs was detected by electron microscopy. Electron microscopy studies showed that the protein VP1-specific transmembrane tunnel structure was not randomly distributed over but was restricted to areas of division sites, predominantly in the middle of the cell or at polar sites [9]. Electron micrographs of a typical bacterial ghost are presented in Figure 1D. To evaluate the safety of the two vaccine candidates, we treated Vero E6 cells with 10 mg of chimeric BGs (equivalent to 1 × 10^10 CFU of bacteria) and 1 × 10^7 CFU of \( E. coli \) O157:H7. We found that the pathogenic bacteria killed nearly 100% of the Vero E6 cells. In contrast, no obvious cytotoxic effects were detected when the Vero E6 cells were treated with 10 mg of EBGs or CBGs (\( p > 0.05 \); Figure 1C). The outer membrane protein intimin was confirmed in EBGs, CBGs, and OBGs by flow cytometry, but the EVP1 and CVP1 were detected only on the surfaces of EBGs and CBGs (Figure 1E).
Figure 1. Verification of the bacterial ghost (BG) vaccine candidates and evaluation of the cytotoxicity. (A) Pyrolysis rates of EVP1 bacterial ghosts (EBGs). (B) Pyrolysis rates of EBGs. The OD₆₀₀ of both EBGs and CVP1 bacterial ghosts (CBGs) were reduced after the shift in temperature. (C) Cytotoxicity analysis of BGs. Serially diluted BGs were incubated with a monolayer of Vero E6 cells for 36 h, and the MTT assay was performed to detect cytotoxicity. (D) The morphology of EBGs and CBGs was assessed by electron microscopy (Scale: E. coli, 12.9 mm × 25 K SE; EBGs, 12.9 mm × 18 K SE; CBGs, 12.9 mm × 37 K SE). (E) Verification of the surface antigens. Flow cytometry was used to detect 1 × 10⁵ HEp-2 cells. Analysis of E. coli O157:H7 chimeric BG outer membrane proteins, which were identified using an EVP1 or CVP1 antibody.

3.2. The Mucosal Immune Response Elicited by Immunization with EBGs or CBGs

In order to investigate the mucosal immune response induced by the various BGs vaccines, we analyzed the IgA antibody titers specific to BGs, intimin, and VP1 proteins in the serum and irrigating solution of the intestinal tract. Both the sera and irrigating solutions were collected on days 0, 7, 14,
21, and 28 (3 mice were used for each time point) after the last immunization and were assayed for the presence of IgA antibodies via (enzyme linked immunosorbent assay) ELISA. The results showed that the IgA titers specific to BGs in the sera and irrigating solutions of mice immunized with EBGs and CBGs increased at day 14 and peaked on day 28 (Figure 2). The IgA titers specific to EBGs or CBGs in the hyperimmune sera of immunized mice reached 1:160 and 1:130, respectively (Figure 2A). The IgA titers specific to EBGs or CBGs in the irrigating solutions of immunized mice reached 1:260 and 1:210, respectively (Figure 2B). The IgA titers specific to intimin in the hyperimmune sera of immunized mice reached 1:100 and 1:130, respectively (Figure 2C). The IgA titers specific to intimin in the irrigating solutions of immunized mice reached 1:130 and 1:210 (Figure 2D). The IgA titers specific to the EVP1 protein in the hyperimmune sera of mice immunized with EBGs reached 1:130, and no antibody titers were detected in mice immunized with CBGs (Figure 2E). The IgA titers specific to the EVP1 protein in the irrigating solutions of mice immunized with EBGs reached 1:60, and no antibody titers were detected in mice immunized with CBGs (Figure 2F). The IgA titers specific to the CVP1 protein in the hyperimmune sera of mice immunized with CBGs reached 1:60, and no antibody titers were detected in mice immunized with EBGs (Figure 2G). The IgA titers specific to the CVP1 protein in the irrigating solutions of mice immunized with CBGs reached 1:130, and no antibody titers were detected in mice immunized with CBGs (Figure 2H).
Figure 2. Detection of specific IgA titers in the sera and irrigating solution of immunized mice. Mice were inoculated intragastrically with BGs. Mice that received a PBS injection were negative controls. The IgA levels in the serum and irrigating solution specific to OBGs (E. coli O157:H7 EDL933 strain without pOEVP1 or pOCVP1 plasmids) were measured for specific proteins (intimin, EVP1, and protein CVP1) by enzyme-linked immunosorbent assays. (A) Time course of serum IgA titers specific
3.3. The Humoral Immune Response against HFMD Virus Elicited by Immunization with EBGs or CBGs

In order to further investigate the humoral immune response induced by the various BG vaccines, we analyzed the IgG antibody titers specific to BGs, intimin, and VP1 proteins in the serum and irrigating solution of the intestinal tract. Samples were collected on days 0, 7, 14, 21, and 28 (3 mice were analyzed at each time point after the last immunization and were assayed for the presence of EVP1 and CVP1-specific antibodies by ELISA. Similar to our previous report [15], the specific antibodies induced by CBGs and EBGs increased persistently over time. We detected high levels of specific anti-EBGs and anti-CBGs IgG antibodies in the samples collected from mice immunized with BGs vaccine candidates. No specific antibodies were detected in the PBS-immunized group (Figure 3A,B). The antibodies specific to intimin, one of the most important factors involved in the adhesion of EHEC, were tested. In contrast to PBS, both the CBGs and EBGs were able to induce significant intimin-specific IgA/IgG antibodies (Figure 3C,D). The IgG titers specific to the EVP1 protein in the sera of mice immunized with EBGs reached 1:130, and no antibody titers were detected in mice immunized with CBGs (Figure 3E). We did not detect specific IgG antibodies in the irrigating solutions from mice immunized with EBGs and CBGs (Figure 3F). The IgG titers specific to the CVP1 protein in the sera of mice immunized with CBGs reached 1:210, and no antibody titers were detected in mice immunized with EBGs (Figure 3G). We did not detect specific IgG antibodies in the irrigating solutions from mice immunized with EBGs and CBGs (Figure 3H). The analysis of IgG subtypes showed a significant increase in IgG1 in the serum of mice immunized with EBGs or CBGs. The titers reached over 1:1000. The titers of IgG2a and IgG2b were also detected, but only reached about 1:200 (Figure 4).
Figure 3. Detection of the specific IgG titers in the sera and irrigating solution of immunized mice. Mice were inoculated intragastrically with BGs. Mice that received a PBS injection were negative controls. The IgG of serum and irrigating solution specific to OBGs and proteins (intimin, EVP1, and protein CVP1) were measured by enzyme-linked immunosorbent assays. (A) Time course of serum IgG titers specific to OBGs. (B) Time course of irrigating solution IgG titers specific to OBGs. (C) Time course of serum IgG titers specific to intimin. (D) Time course of irrigating solution IgG titers specific to intimin. (E) Time course of serum IgG titers specific to protein EVP1. (F) Time course of irrigating solution IgG titers specific to protein EVP1. (G) Time course of serum IgG titers specific to protein
CVP1. (H) Time course of irrigating solution IgG titers specific to protein CVP1. Data are from two independent experiments. * $p < 0.01$.

![Graph showing antibody subtype profiles](image)

**Figure 4.** Antibody subtype profiles of mice immunized with various vaccines. Mice were inoculated intragastrically with BGs. Mice that received a PBS injection were negative controls. Two weeks after the last immunization, both the sera and irrigating solution were collected from the experimental mice, and antibody titers were evaluated by an ELISA. Data are from two independent experiments. Each bar represents the mean titers of antibodies in the same group. * $p < 0.01$, as compared with the PBS group.

3.4. Efficacy of EBGs and CBGs Immunization in Generating Protective Immunity against the HFMD Virus

While the vaccine approach has great potential for HFMD prevention, immunoprotection against HFMD has not been achieved. In order to study the protective effect of EBGs and CBGs, pups were challenged with an intraperitoneal injection of the EV71 and CB3 viruses. The results showed that EBGs protected mice against 2 LD$_{50}$ of EV71 and CB3 infections (Figure 5A,B). When mice were challenged with 5 LD$_{50}$ EV71, 50% of the suckling mice immunized with EBGs survived; however, none of the suckling mice immunized with CBGs survived. CBGs provided an 87.5% protective rate against 2 LD$_{50}$ CB3 infection and 37.5% protective rate against 5 LD$_{50}$ CB3 infection, whereas there were no surviving mice in the 2 LD$_{50}$ EBGs-immunized group for either challenge. There were no survivors in control groups.

3.5. Efficacy of EBGs and CBGs immunizations in generating cross-protective immunity against *E. coli* O157:H7

EBGs and CBGs not only displayed stronger protection against EV71 and CB3 infections but also displayed cross-protection against *E. coli* O157:H788321 infection. EBGs provided a similar ($p > 0.05$) protective rate (14/20, 70%) as the CBGs (15/20, 75%) when the challenge dose was 20 LD$_{50}$ (Figure 5C). When the intragastric challenge dose was increased to 50 LD$_{50}$, there were no survivors in either immunized group (data not shown). No mice survived in the PBS-immunized groups when challenged with either the high or low dose.
Figure 5. Vaccine candidates protected mice against a lethal dose of toxins. (A) Survival rates of the pups of mice immunized with BGs and challenged with 2 LD<sub>50</sub> CB3, 2 LD<sub>50</sub> EV71, or 5 LD<sub>50</sub> EV71. In comparison with mice immunized with PBS, all vaccine candidates increased the survival rate (p < 0.001; n = 20 mice/group). (B) Survival rates for the pups of mice immunized with BGs and challenged with 2 LD<sub>50</sub> EV71, 2 LD<sub>50</sub> CB3, or 5 LD<sub>50</sub> CB3. In comparison with mice immunized with PBS, all vaccine candidates increased the survival rate (p < 0.001; n = 20 mice/group). (C) Survival rate (D) body weight changes for wild-type mice immunized with BGs and challenged with 20 LD<sub>50</sub> (2 × 10<sup>9</sup> CFU) of viable <i>E. coli</i> O157:H788321 strain. In comparison with mice immunized with PBS, all vaccine candidates increased the survival rate (p < 0.001; n = 20 mice/group). Similar results were observed in two independent experiments. Survival data were analyzed by log-rank tests. Data are from two independent experiments.

4. Discussion

In recent years, there has been an increase in the occurrence of HFMD, which has no effective treatment. Disease prevention is a promising approach to defend against HFMD virus infection, which deserves further exploration [16]. As mentioned previously, capsid protein VP1 is a major virulence determinant of the HFMD virus. A number of studies have demonstrated that antibodies induced by VP1-based vaccines can efficiently block viral replication in tissue [21,22]. Although these VP1 protein vaccine candidates can be produced easily, they are less immunogenic and require a delivery system or the addition of adjuvants. BGs are produced by the expression of the cloned PhiX174 gene E in Gram-negative bacteria [23], which can be used as a delivery system for foreign subunit antigens. It has been demonstrated that foreign antigens presented by BGs to the immune system can induce strong immune responses [14,24,25].

Therefore, we designed two VP1 chimeric antigens of BGs as vaccine candidates in this study. We immunized mice with the two chimeric BGs and challenged them with <i>E. coli</i> O157:H7. We also challenged suckling mice with EV71 and CB3 virus separately. In this study, it was verified for the first time that two BG vaccines based on the VP1 proteins induced significant mucosal and humoral immunity. We detected high levels of specific IgG and IgA titers 7 days after the first immunization, and the titers were much higher on day 7 after a booster. From these results, we concluded that both
CBGs and EBGs were highly immunogenic for mice. To investigate which subtype was predominant in mice immunized with the vaccine candidates, the IgG subtypes were assayed by ELISA. We found a significant increase in the absorbance for antigen-specific IgG1, IgG2a, and IgG2b, but not IgG3.

Recombinant VP1 protein formulated with complete Freund’s adjuvant can elicit neutralizing antibody responses in mice. Synthetic immunogens based on the neutralization epitopes of EV71 also require complete Freund’s adjuvant, which is not acceptable for use in humans [16]. Vaccination with DNA plasmid constructs encoding VP1 resulted in low neutralizing responses. Vaccination of neonatal mice with an adenovirus vector expressing a conserved neutralization epitope conferred protection against lethal EV71 challenge. Thus, delivery systems are very important for HFMD virus vaccine development. Here, we selected BGs as a delivery system for our vaccine candidates. In order to evaluate the protection conferred by the vaccine candidates, the newborn mice were challenged with an intraperitoneal injection of EV71 and CB3 virus separately. We found that the two vaccine candidates protected mice against HFVD virus infection.

The immunized adult mice were intragastrically challenged with *E. coli* O157:H7. We found that the two vaccine candidates also protected mice against *E. coli* infection. Intimin protein, a membrane component on the surface of *E. coli* O157:H7, is an important factor for bacterial attaching/effacing (A/E), and the levels of intimin specific antibodies have been demonstrated to be associated with protection against this bacterium [26,27]. In our study, we evaluated high levels of anti-intimin antibody responses. Therefore, the novel BG vaccine candidates have the potential to provide protection against the adhesion of bacteria. We did not find a significant difference in the protection of CBG-and EBG-immunized mice challenged with *E. coli*.

To summarize, our chimeric BGs vaccine candidates elicit a higher mucosal immune response and provide greater protection for the host against HFMD. Our data decisively demonstrated that our vaccine candidates also conferred cross-protection against *E. coli* O157:H7, indicating that the BGs can be used as a relatively efficacious vector for vaccine development against HFMD.

**Author Contributions:** All authors discussed the results and implications of the manuscript. H.W. and D.L. conceived the study, supervised the project, analyzed the data, and wrote the paper. S.G., N.N., Z.H., J.L., Y.S., T.L., F.C., J.W. and Z.L. performed the experiments and analyzed the data. D.L. advised on statistical evaluations. S.G., N.N. and Y.S. contributed equally to this work.

**Funding:** National Key Research Project: 2018ZX10101003-005-001; National Natural Science Foundation of China: 31870156; National Key Lab Research program: SKLPBS1811

**Acknowledgments:** All animal studies were conducted in accordance with the Beijing Institute of Microbiology and Epidemiology Animal Care and Use Committee guidelines. We thank all employees of the Beijing Institute of Microbiology and Epidemiology Animal Facilities for dedicated breeding and care of the mice used in these studies.

**Conflicts of Interest:** The authors have no financial conflicts of interest.

**References**

1. Wang B.; Li J.; Wang Y.; Du N.; Sun L.; Xiao H.; Zhao Y.; Bao W.; Zhang W. Understanding the epidemiological characteristics of EV71 and CVA16 infection to aid the diagnosis and treatment of hand, foot, and mouth disease. *J. Med Virol.* 2019, 91, 201–207.

2. Pathinayake P.S.; Hsu A.C.; Wark P.A: Innate immunity and immune evasion by enterovirus 71. *Viruses* 2015, 7, 6613–6630.

3. Lin Y.L.; Cheng P.Y.; Chin C.L.; Huang L.M.; Lin S.Y.; Chiang B.L. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine. *Vaccine* 2018, 36, 4331–4338.

4. Wang L.C.; Kao C.M.; Ling P.; Su I.J.; Chang T.M.; Chen S.H. CD4 T-cell-independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads. *Clin. Dev. Immunol.* 2012, 2012, 580696.
5. Tung W.S.; Bakar S.A.; Sekawi Z.; Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. *Genet. Vaccines Ther.* **2007**, *5*, 6.

6. Crawford N.W.; Graham S.M. EV71 vaccine: protection from a previously neglected disease. *Lancet* **2013**, *381*, 1968–1970.

7. Park K.B.; Lim B.K.; Ye M.B.; Chung S.Y.; Nam J.H. A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response. *Acta. Virolologica*. **2012**, *56*, 337–342.

8. Xu L.; He D.; Li Z.; Zheng J.; Yang L.; Yu M.; Yu H.; Chen Y.; Que Y.; Shih J.W.; et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. *Theranostics* **2014**, *4*, 498–513.

9. Witte A.; Warner G.; Sulzner M.; Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. *Arch. Microbiol.* **1992**, *157*, 381–388.

10. Witte A.; Lubitz W. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli. *Eur. J. Biochem.* **1989**, *180*, 393–398.

11. Riedmann E.M.; Kyd J.M.; Cripps A.W.; Lubitz W. Bacterial ghosts as adjuvant particles. *Expert Rev. Vaccines* **2007**, *6*, 241–253.

12. Jiao H.; Yang H.; Zhao D.; Chen J.; Zhang Q.; Liang J.; Yin Y.; Kong G.; Li G. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using ghosts as vector and adjuvant. *Vaccine* **2018**, *36*, 4532–4539.

13. Eko F.O.; Schukovskaya T.; Lotzmanova E.Y.; Firstova V.V.; Emalyanova N.V.; Klueva S.N.; Kravtzov A.L.; Livanova L.F.; Kutyrev V.V.; Igietseme J.U.; et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. *Vaccine* **2003**, *21*, 3663–3674.

14. Cai K.; Tu W.; Liu Y.; Li T.; Wang H. Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7. *Sci. Rep.* **2015**, *5*, 17479.

15. Cai K.; Tu W.; Liu Y.; Li T.; Wang H. Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7. *Sci. Rep.* **2015**, *5*, 17479.

16. Chong P.; Liu C.; Chow Y.; Chou A.; Kleins M. Review of enterovirus 71 vaccines. *Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am.* **2015**, *60*, 797–803.

17. Pistor S.; Hobom G. Expression of viral hemagglutinin on the surface of E. coli. *Klin. Wochenschr.* **1988**, *66*, 110–116.

18. Mader H.J.; Szostak M.P.; Hensel A.; Lubitz W.; Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. *Vaccine* **1997**, *15*, 195–202.

19. Cai K.; Gao X.; Li T.; Hou X.; Wang Q.; Liu H.; Xiao L.; Tu W.; Liu Y.; Shi J.; et al. Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. *Can. J. Microbiol.* **2010**, *56*, 389–398.

20. Fanghong Chen; Xiong L.; Nan Nan; Zhan Li; Nianzhi Ning; Deyan Luo; Hui Wang. VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment. *Front. Immunol* **2019**, *10*, 2564.

21. Wu C.Y.; Yu S.L.; Chen Y.T.; Chen Y.H.; Hsiao P.W.; Chow Y.H.; Chen J.R. The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus. *PLoS One* **2019**, *14*, e0210553.

22. Zheng H.; Wang J.; Li B.; Guo L.; Li H.; Song J.; Yang Z.; Li H.; Fan H.; Huang X.; et al. Correction: A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice. *J. Immunol.* **2019**, *202*, 1905–1906.
23. Walcher P.; Mayr U.B.; Azimpour-Tabrizi C.; Eko F.O.; Jechlinger W.; Mayrhofer P.; Alefantis T.; Mujer C.V.; DelVecchio V.G.; Lubitz W. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. *Expert Rev. Vaccines* 2004, 3, 681–691.

24. Jechlinger W.; Haller C.; Resch S.; Hofmann A.; Szostak M.P.; Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. *Vaccine* 2005, 23, 3609–3617.

25. Ebensen T.; Paukner S.; Link C.; Kudela P.; de Domenico C.; Lubitz W.; Guzman C.A. Bacterial ghosts are an efficient delivery system for DNA vaccines. *J. Immunol.* 2004, 172, 6858–6865.

26. Klose M.; Jahnig F.; Hindennach I.; Henning U. Restoration of membrane incorporation of an *Escherichia coli* outer membrane protein (OmpA) defective in membrane insertion. *J. Biol. Chem.* 1989, 264, 21842–21847.

27. Dornmair K.; Kiefer H.; Jahnig F. Refolding of an integral membrane protein. OmpA of *Escherichia coli*. *J. Biol. Chem.* 1990, 265, 18907–18911.